Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
Top Cited Papers
Open Access
- 25 March 2019
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 6 (1), e000397
- https://doi.org/10.1136/bmjresp-2018-000397
Abstract
Introduction Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise the safety and tolerability profile of nintedanib and to investigate its effects on survival. Methods Data from patients treated with ≥1 dose of nintedanib 150 mg two times per day or placebo in the 52-week TOMORROW trial and/or its open-label extension; the two 52-week INPULSIS trials and/or their open-label extension, INPULSIS-ON; and a Phase IIIb trial with a placebo-controlled period of ≥6 months followed by open-label nintedanib were pooled. All adverse events, irrespective of causality, were included in descriptive analyses. Parametric survival distributions were fit to pooled Kaplan-Meier survival data from the trials and extrapolated to estimate long-term survival. Results There were 1126 patients in the pooled nintedanib group and 565 patients in the pooled placebo group. The mean duration of nintedanib treatment was 28 months. No new safety signals were observed. Incidence rates of bleeding, liver enzyme elevations and cardiovascular events were consistent with those observed in the INPULSIS trials. Diarrhoea was reported at a lower event rate in the pooled nintedanib group than in nintedanib-treated patients in the INPULSIS trials (76.5 vs 112.6 events per 100 patient exposure-years) and infrequently led to permanent treatment discontinuation (3.6 events per 100 patient exposure-years). Based on the Weibull distribution, mean (95% CI) survival was estimated as 11.6 (9.6, 14.1) years in nintedanib-treated patients and 3.7 (2.5, 5.4) years in placebo-treated patients. Conclusions Based on pooled data from six clinical trials, the adverse event profile of nintedanib was manageable for most patients. Exploratory analyses based on extrapolation of survival data suggest that nintedanib extends life expectancy in patients with IPF.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 27 references indexed in Scilit:
- Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11The Lancet Respiratory Medicine, 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- Mechanisms of TKI-induced diarrhea in cancer patientsCurrent Opinion in Supportive & Palliative Care, 2013
- Burden of illness in idiopathic pulmonary fibrosisJournal of Medical Economics, 2012
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2011
- Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New MillenniumSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis: A Population-Based StudySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Severity of Illness and Outcome in Patients With End-Stage Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation: ResponseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Adverse effects of anticancer agents that target the VEGF pathwayNature Reviews Clinical Oncology, 2009
- A convenient approximation of life expectancy (the “DEALE”): I. validation of the methodAmerican Journal Of Medicine, 1982